Gain Therapeutics (NASDAQ:GANX) Rating Reiterated by HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 479.71% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, March 27th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target on shares of Gain Therapeutics in a research report on Tuesday, April 23rd.

Gain Therapeutics Stock Performance

Shares of Gain Therapeutics stock opened at $1.38 on Thursday. Gain Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.33. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average price of $1.95 and a 200-day moving average price of $3.19. The company has a market cap of $24.91 million, a PE ratio of -0.92 and a beta of 0.35.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Equities analysts anticipate that Gain Therapeutics will post -1.03 earnings per share for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.